GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune
Jessica D Hathaway-Schrader1, Duncan Norton1, Katherine Hastings1
1Department of Microbiology and Immunology, Hollings Cancer Center, Children's Research Institute, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425, USA.
Abstract:
Melanoma is an aggressive skin cancer that has become increasingly prevalent in western populations. Current treatments such as surgery, chemotherapy, and high-dose radiation have had limited success, often failing to treat late stage, metastatic melanoma. Alternative strategies such as immunotherapies have been successful in treating a small percentage of patients with metastatic disease, although these treatments to date have not been proven to enhance overall survival. Several melanoma antigens (Ags) proposed as targets for immunotherapeutics include tyrosinase, NY-ESO-1, gp-100, and Mart-1, all of which contain both human leukocyte antigen (HLA) class I and class II-restricted epitopes necessary for immune recognition. We have previously shown that an enzyme, gamma-IFN-inducible lysosomal thiol-reductase (GILT), is abundantly expressed in professional Ag presenting cells (APCs), but absent or expressed at greatly reduced levels in many human melanomas. In the current study, we report that increased GILT expression generates a greater pool of antigenic peptides in melanoma cells for enhanced CD4+ T cell recognition. Our results suggest that the induction of GILT in human melanoma cells could aid in the development of a novel whole-cell vaccine for the enhancement of immune recognition of metastatic melanoma.
Insights
Increasing gamma-interferon-inducible lysosomal thiol-reductase (GILT) in melanoma cells enhances immune recognition. This could lead to new whole-cell vaccines for treating metastatic melanoma.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Melanoma is an aggressive skin cancer with limited treatment success for metastatic stages.
- Current immunotherapies show promise but do not consistently improve overall survival.
- Melanoma antigens targeted by immunotherapeutics require both human leukocyte antigen (HLA) class I and class II-restricted epitopes.
Purpose of the Study:
- To investigate the role of gamma-interferon-inducible lysosomal thiol-reductase (GILT) in melanoma antigen presentation.
- To determine if enhanced GILT expression can improve melanoma cell recognition by CD4+ T cells.
Main Methods:
- Assessed GILT expression levels in melanoma cells.
- Studied the effect of increased GILT expression on the generation of antigenic peptides.
- Evaluated the impact of GILT on CD4+ T cell recognition of melanoma cells.
Main Results:
- GILT is expressed in professional antigen-presenting cells (APCs) but is low or absent in many human melanomas.
- Increased GILT expression in melanoma cells generates a larger pool of antigenic peptides.
- Enhanced GILT expression leads to improved CD4+ T cell recognition of melanoma cells.
Conclusions:
- Inducing GILT in human melanoma cells can enhance immune recognition.
- This strategy may facilitate the development of novel whole-cell vaccines for metastatic melanoma.
- Targeting GILT offers a potential new avenue for melanoma immunotherapy.
Related Concept Videos
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
01:31Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...